



November 4, 2011

3-D Matrix, Ltd.

**3-D Matrix nominated as a joint research partner
in Grants-in Aid for Scientific Research Project
on triple negative breast cancer treatment**

3-D Matrix, Ltd. (3DM) was nominated by Ministry of Health, Labour, and Welfare as a joint partner with National Cancer Center Hospital (Deputy Director: Yasuhiro Fujiwara) and National Cancer Center Research Institute (Deputy Director: Takahiro Ochiai) for a project of Grants-in-Aid for Scientific Research to cure triple negative breast cancer by nucleic acid medicine.

Breast cancer occurs to one per thirty Japanese women and is said the most common cancer to affect Japanese women. Since it is said that usual treatments are not effective in the case called “triple negative” of breast cancer, fundamental treatments which cancer stem cells are targeted by are desired. Nucleic acid medicine, whose delivery to a target has challenges, is expected as a fundamental medicine for cancer. Surfactant Peptide A6K developed by 3DM is expected to be an effective delivery carrier through past animal studies.

This project aims to start a first-in-human clinical trial at National Cancer Center Research Institute for triple negative breast cancer with a drug product whose carrier is Peptide A6K developed by 3DM and nucleic acid medicine which targets and inhibits to express RPN2 gene expressed in breast cancer stem cells specifically. This project is expected to be the driving force of nucleic acid medicine.

This nomination will give a research and development grant to the project itself and does not influence the earning forecast of 3DM at this moment.

3DM promotes research and development of this project and seeking new availability and commercialization of peptide.